🔎 Trials Near Me

Utama › Karsinoma Sel Skuamosa Esofagus › Ohio

Kajian klinikal Karsinoma Sel Skuamosa Esofagus di Ohio

8 kajian untuk Karsinoma Sel Skuamosa Esofagus sedang mencari peserta di lokasi di Ohio.

Bandar di Ohio

Teks kajian rasmi (Bahasa Inggeris)

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

  • ALX Center 10, Columbus
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07085091

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • UH Cleveland Medical Center, Cleveland
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07109726

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

  • University Hospitals Cleveland Medical Center, Cleveland
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT07217171

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

  • Research Site, Columbus
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Sep 2026 · NCT06535607

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

  • University Hospitals Cleveland Medical Center, Cleveland
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Jul 2026 · NCT05208762

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

  • Research Site, Cleveland
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 12 Jun 2026 · NCT07284186

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

  • Research Site 138, Canton
  • Research Site 113, Cincinnati
  • Research Site 131, Dayton
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Nov 2025 · NCT05914116

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.